Biophytis

Biophytis ROIC

The Return on Invested Capital (ROIC) of Biophytis (ALBPS.PA) as of Oct 29, 2026 is -5,964.94 %. In the previous year, Return on Invested Capital (ROIC) was -385.81 % — a change of 1,446.06% (lower).

ROIC

-5,964.94 %

YoY

1,446.06%

Last updated:

Return on Invested Capital (ROIC) of Biophytis is 2024 -5,964.94 % . Return on Invested Capital (ROIC) of Biophytis was 2023 -385.81 % . It decreases by 1,446.06% lower compared to the previous year.

The Biophytis ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2017
-51.32 EUR
Jan 1, 2018
-91.80 EUR
Jan 1, 2019
-245.89 EUR
Jan 1, 2020
-223.95 EUR
Jan 1, 2021
-143.33 EUR
Jan 1, 2022
-190.66 EUR
Jan 1, 2023
-385.81 EUR
Jan 1, 2024
-5,964.94 EUR
The Biophytis ROIC history
YEARROICYoY
-5,964.94 %+1,446.06%
-385.81 %+102.36%
-190.66 %+33.02%
-143.33 %-36.00%
-223.95 %-8.92%
-245.89 %+167.85%
-91.80 %+78.89%
-51.32 %-63.62%
-141.08 %+237.05%
-41.86 %-122.09%
189.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biophytis Stock analysis

What does Biophytis do? Biophytis SA develops therapeutics for sarcopenia and Age Related Macular Degeneration, focusing on restoring muscular and visual functions. The company's clinical programs include Sarconeos (BIO101) for sarcopenia and Macuneos (BIO201) for ARMD, developed simultaneously in the U.S. and domestic markets. Biophytis generates revenue through clinical development partnerships and potential future product sales, targeting pharmaceutical companies and healthcare providers seeking treatments for aging-related conditions. The company's primary products are Sarconeos (BIO101) and Macuneos (BIO201), with clinical development ongoing for both. Biophytis targets healthcare providers and pharmaceutical companies as key buyers, particularly those focused on aging diseases. The firm's strategy involves advancing drug candidates through clinical trials to secure regulatory approvals and commercial partnerships. Biophytis SA's business model centers on the development of two drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), for sarcopenia and ARMD respectively. The company's revenue streams are derived from clinical development collaborations and potential future licensing agreements with pharmaceutical firms. The target market comprises healthcare institutions and pharmaceutical companies seeking innovative treatments for age-related medical conditions. Biophytis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biophytis stock

Return on Invested Capital (ROIC) of Biophytis is -5,964.94 % in 2024.

Return on Invested Capital (ROIC) of Biophytis changed from -385.81 % to -5,964.94 %, representing a 1,446.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Biophytis since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Biophytis with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biophytis

All Key Metrics — Biophytis